Christine Sanders

Christine Sanders

Auto-generated profile, based on publicly available information

Christine Sanders

Institute of Pathology, University Hospital Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
RHRacha Hosni
Racha Hosni
NKNiklas Klümper
Niklas Klümper
CSChristine Sanders
Christine Sanders
SHSana Hosni
Sana Hosni
VBVittorio Branchi
Vittorio Branchi
MTMarieta Toma
Marieta Toma
Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray (n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro. IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.

3 November 2025
Verified
Other
Open access
PDF file
RHRacha Hosni
Racha Hosni
NKNiklas Klümper
Niklas Klümper
CSChristine Sanders
Christine Sanders
SHSana Hosni
Sana Hosni
VBVittorio Branchi
Vittorio Branchi
MTMarieta Toma
Marieta Toma
Complete and incomplete expression patterns of Her2 and Her3 in cholangiocarcinoma.

3 November 2025
Verified
Other
Open access
RHRacha Hosni
Racha Hosni
NKNiklas Klümper
Niklas Klümper
CSChristine Sanders
Christine Sanders
SHSana Hosni
Sana Hosni
VBVittorio Branchi
Vittorio Branchi
MTMarieta Toma
Marieta Toma
Percent TROP2 positive cells, median fluorescence intensity (MFI) of TROP2, and IC50 intervals of sacituzumab govitecan in cholangiocarcinoma (CC) PDO cultures.

3 November 2025
Verified
Other
Open access
RHRacha Hosni
Racha Hosni
NKNiklas Klümper
Niklas Klümper
CSChristine Sanders
Christine Sanders
SHSana Hosni
Sana Hosni
VBVittorio Branchi
Vittorio Branchi
MTMarieta Toma
Marieta Toma
HER2/HER3 IHC scoring criteria following gastric cancer guidelines. A table listing the definition and interpretation of the HER2 and HER3 IHC scoring system.

3 November 2025
Verified
Other
Open access
PDF file
RHRacha Hosni
Racha Hosni
NKNiklas Klümper
Niklas Klümper
CSChristine Sanders
Christine Sanders
SHSana Hosni
Sana Hosni
VBVittorio Branchi
Vittorio Branchi
MTMarieta Toma
Marieta Toma
TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).

3 November 2025
Verified
Other
Open access
RHRacha Hosni
Racha Hosni
NKNiklas Klümper
Niklas Klümper
CSChristine Sanders
Christine Sanders
SHSana Hosni
Sana Hosni
VBVittorio Branchi
Vittorio Branchi
MTMarieta Toma
Marieta Toma
Parental tumor localization of cholangiocarcinoma (CC) PDO cultures.